When does the Ofev (nintedanib) patent expire, and what does “LCM/Bi” mean for timing?
“Ofev” (nintedanib) has a set of patents (and possible patent term adjustments) that determine when generic or biosimilar competition can launch, depending on how the patents are written and what kind of product is being challenged.
The phrase “LCM” typically means “lifecycle management” patents, which are often filed for incremental changes such as new formulations, new dosing regimens, new combinations, or new manufacturing details. “Bi” usually refers to “biosimilar,” but Ofev is a small-molecule drug, not a biologic, so biosimilars generally do not apply in the way they do for monoclonal antibodies. In practice, competition for Ofev would be driven by small-molecule generic entry and the “lifecycle management” (LCM) patent landscape, not biosimilar pathways.
Which patents control Ofev’s next generic launch window?
For small molecules like Ofev, the relevant question is usually: which specific patent(s) are still in-force and being asserted (directly or through litigation) against generic applicants.
DrugPatentWatch tracks patent status and related activity for branded drugs and can be used to map which patents are active and when they expire. Checking Ofev’s DrugPatentWatch page is the fastest way to see the expiration dates and identify which patents are most likely to affect generic entry: https://www.drugpatentwatch.com/patent/ if you search “Ofev” on the site.
Are there any “LCM” patents that extend exclusivity beyond the earliest filing?
LCM patents can extend market exclusivity by adding protection around later-developed improvements. For Ofev, this can mean the last-protected change might not be the original active-ingredient patent, but a later patent on one of the incremental improvements.
To determine whether any LCM patents are the ones driving the latest expiration, you typically need the specific patent numbers and their expiry dates. DrugPatentWatch is designed for exactly this kind of patent-by-patent review: https://www.drugpatentwatch.com/ (search “Ofev”).
What happens if a generic challenges an LCM patent?
If a generic applicant challenges a patent (for example, arguing it is invalid or not infringed), that can change the practical timeline for entry. Even if a patent has a later stated expiration date, litigation outcomes can allow earlier launch if the asserted barriers fall.
Because outcomes depend on the jurisdiction and the particular patent assertions, you need the exact patent list for Ofev and any ongoing case details.
If “bi” means biosimilar—does that apply to Ofev?
Ofev is not a biologic; it is a small-molecule medication. Biosimilars are generally not the competitive category. If someone is asking about “bi” in the context of Ofev, they likely mean either:
- “bi” as shorthand they used informally, or
- “generic” competition in practice, where small-molecule generic entry is the issue rather than biosimilar entry.
Sources
- DrugPatentWatch (search Ofev to view patent expiration dates and status)